Skip to main content
. Author manuscript; available in PMC: 2009 May 15.
Published in final edited form as: Clin Cancer Res. 2008 May 15;14(10):3216–3222. doi: 10.1158/1078-0432.CCR-07-4932

Table 2.

Adjusted odds ratio of EGF A61G polymorphism overall, and in subsets defined by the presence of absence of concurrent BE

Category Crude Analysis Adjusted Analysis *
G/G vs A/A A/G vs A/A G/G vs A/A A/G vs A/A
OR (95% CI) P-value
(cases/
controls)		 OR (95% CI) P-value
(cases/
controls)		 OR (95% CI) P-value
(cases/
controls)		 OR (95% CI) P-value
(cases/
controls)
All Adenocarcinomas 1.83 (1.2-2.7) P=0.003
(312/447)		 1.17 (0.8-1.6) P=0.35
(312/447)		 1.81 (1.2-2.7) p=0.005
(307/443)		 1.20 (0.9-1.7) p=0.55
(307/443)
Subset with histologic
Barrett's esophagus on
endoscopy/resection 		2.29 (1.4-3.8) P=0.001
(145/447)		 1.25 (0.8-1.9) P=0.32
(145/447)		 2.18 (1.3-3.7) 0.004
(143/443)		 1.31 (0.8-2.1) 0.24
(143/443)
Subset of resected
patients without
histologic Barrett's
esophagus 		1.38 (0.8-2.6) P=0.31
(86/447)		 0.91 (0.5-1.5) P=0.71
(86/447)		 1.37 (0.7-2.6) 0.65
(84/443)		 0.88 (0.5-1.5) 0.33
(84/443)
*

adjusted for age, gender, smoking status, pack-years, healthy adult BMI